探索系统性硬化症患者的最佳随访方案:荷兰多中心随机对照试验的研究方案
本研究为荷兰三中心非劣效随机对照试验,拟纳入250例系统性硬化症患者,按已发表风险预测模型分为低、中、高风险,将低或中风险者随机分为门诊常规评估组与年度Care Pathway广泛评估对照组,主要结局为通过问卷评估的医疗资源利用。
要点
- 目前缺乏系统性硬化症随访频率与强度的循证指南,基于专家意见推荐年度广泛评估。
- 研究纳入低或中风险进展的系统性硬化症患者,随机比较门诊评估与Care Pathway年度广泛评估。
- 主要结局为医疗资源利用,定义为与医疗专业人员接触次数,通过问卷评估。
核心结论
- 该研究旨在评估对于疾病进展低风险的系统性硬化症患者,常规门诊评估是否可作为Care Pathway年度广泛评估的可接受替代方案。
研究设计与样本
- 多中心(n=3)非劣效随机对照试验,拟招募并随机250例系统性硬化症患者。
- 根据已发表的风险预测模型将患者分为疾病进展低、中、高风险三类,低或中风险者随机分为门诊随访(干预组)与按年度Care Pathway常规护理随访(对照组)。
- 研究访视后一年,所有患者均在Care Pathway中评估。
主要发现
- 原文未报告研究结果。
关键数值与推荐
- 主要结局为医疗资源利用,定义为与医疗专业人员接触次数,通过问卷评估,采用描述性统计和线性回归分析。
- 次要结局包括疾病进展、患者对疾病和照护的感知以及健康相关生活质量。
- Care Pathway标准化评估包括年度6分钟步行试验、心电图、实验室检查、mRSS和肺功能检查。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently, evidence-based guidelines for the frequency and intensity of follow-up of systemic sclerosis (SSc) patients are not available. Based on expert opinion, an annual extensive evaluation is recommended. A multidisciplinary Care Pathway that integrates this annual extensive evaluation at the Leiden University Medical Center has shown increased patient satisfaction, decreased healthcare utilization, and improved outcomes in SSc patients (1, 2). However, for a subgroup of SSc patients with relatively mild disease, this annual extensive evaluation might be redundant. Therefore, this study aims to evaluate whether assessment in a regular outpatient clinic setting is an acceptable alternative to extensive annual evaluation in the Care Pathway in SSc patients with a low risk of disease progression. METHODS: This study is designed as a multicenter (n = 3) non-inferiority randomized controlled trial. SSc patients are categorized into three categories for risk of disease progression (low, intermediate, or high) based on a previously published risk prediction model (3). Patients with a predicted low or intermediate risk of disease progression are randomized between (1) follow-up in the outpatient clinic (intervention) and (2) follow-up via usual care according to the annual Care Pathway (control group). The year after the "study visit," all patients are evaluated in the Care Pathway. In this study, 250 patients will be recruited and randomized. The primary outcome is healthcare utilization, which will be assessed via questionnaires. Secondary outcome measures include disease progression, patients' perception of disease and care, and health-related quality of life. Healthcare utilization is defined as the number of contacts with a healthcare professional and will be analyzed using descriptive statistics and linear regression analysis. DISCUSSION: There is an unmet need for tailor-made care for SSc patients in accordance with disease activity, and evidence-based guidelines regarding the follow-up of SSc patients are lacking. This is the first randomized controlled trial evaluating the optimal follow-up for SSc patients at low risk of disease progression. Results of this study will show whether routine assessment at the outpatient clinic is an acceptable alternative to assessment in a standardized care setting including an annual 6-min walk test, an ECG, lab, mRSS, and a pulmonary function test. TRIAL REGISTRATION: ClinicalTrials.gov NCT05103553. Registered on October 11, 2021.
引用
- Hoekstra EM, Liem SIE, Ahmed S, et al. Exploring the optimal follow-up for systemic sclerosis patients: study protocol for a Dutch multicenter randomized controlled trial. Trials. 2026. PMID: 41689135. doi:10.1186/s13063-026-09494-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。